Le Lézard
Classified in: Health, Business
Subjects: TNM, ACC

Apollo Medical Holdings Changed Its Fiscal Year End



GLENDALE, Calif., Feb. 23, 2018 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed" or the "Company") (NASDAQ: AMEH), an integrated population health management company, today announced that, as previously reported on a Current Report on Form 8-K to the Securities and Exchange Commission, the Company's Board of Directors approved a change in its fiscal year end from March 31 to December 31 in connection with the completion of its business combination (the "Merger") with Network Medical Management, Inc. ("NMM"), a management services organization ("MSO"), to correspond with the fiscal year-end of NMM.  As a result of this change, the Company's first fiscal year-end following the Merger was December 31, 2017, and the end of the Company's first quarter following the Merger will be March 31, 2018. The Company plans to report the financial results reflecting the combined operations for the fiscal year ended December 31, 2017 on a Form 10-K on or prior to April 2, 2018.  The Company's 2018 fiscal year commenced on January 1, 2018.

About Apollo Medical Holdings, Inc. (ApolloMed)

ApolloMed is a leading physician-centric integrated population health management company, which, together with its subsidiaries, including a Next Generation Accountable Care Organization ("NGACO"), and its affiliated Independent Physician Associations (each, an "IPA"), are working to provide coordinated, outcomes-based high-quality medical care for patients, particularly senior patients and patients with multiple chronic conditions, in a cost-effective manner.  Led by a management team with over two decades of experience, ApolloMed is addressing the healthcare needs of its patients by leveraging its integrated health management and healthcare delivery platform that includes: Network Medical Management (MSO),  Apollo Medical Management (MSO), APA ACO (NGACO), ApolloMed Hospitalists (IPA), Allied Physicians of California (IPA), Maverick Medical Group (IPA), Apollo Care Connect (Digital Population Health Management Platform) and ApolloMed Palliative Care Services (Hospice/Palliative Care and Home Health Care).  ApolloMed strives to improve medical outcomes with high-quality, cost-efficient care.  For more information, please visit www.apollomed.net.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements about the Company's future public filings. Forward-looking statements reflect current views with respect to future events, and therefore, cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, associated with such statements, many of which are beyond the control of the Company, which could cause the actual results to be materially different than those that may be anticipated. Examples of such risks and uncertainties include factors described from time to time in the Company's reports to the Securities and Exchange Commission (including without limitation the "Risk Factors" discussed in the Company's Quarterly Report on Form 10-Q filed on November 14, 2017 for the quarter ended September 30, 2017, Annual Report on Form 10-K filed on June 29, 2017 for the year ended March 31, 2017, Registration Statement Amendment No. 2 on Form S-4/A filed on November 9, 2017, and Rule 424(b)(3) prospectus filed on November 15, 2017). Should one or more of these risks or uncertainties materialize, or should any expectations or assumptions underlying the relevant forward-looking statements prove incorrect, the actual results may vary materially from those described in such statements as being expected, anticipated, intended, planned, believed, sought, estimated or projected. Investors and other readers, therefore, should not place reliance on any forward-looking statements or use any historical trends to anticipate or predicate results or trends in future periods. Any statements included herein are made only as of the date hereof. The Company undertakes no obligation to update or revise any statement to reflect the impact of circumstances or events that arise after the date hereof, except as required by law, and also undertakes no obligation to correct or update information prepared by third parties.

FOR MORE INFORMATION, PLEASE CONTACT:

Gary Augusta
President
Apollo Medical Holdings, Inc.
(818) 839-5200
gaugusta@apollomed.net                                        

 

SOURCE Apollo Medical Holdings, Inc.


These press releases may also interest you

at 02:00
SACRAMENTO, Calif., Sept. 22, 2018 /PRNewswire-PRWeb/ -- The health risks associated with heart disease, stroke, and cancer are well-known. Less well-known, however, is the serious health risk that particularly affects older adults ? the risk of...

21 sep 2018
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 22, 2018 to file lead plaintiff applications in a securities class action lawsuit against Nevro Corp. , if they purchased the Company's shares between...

21 sep 2018
ROCKVILLE, Md., Sept. 21, 2018 /PRNewswire-PRWeb/ -- - Bharti Shah, Chief Executive Officer CTIS, Inc., Rockville, MD based Health Informatics company, today announced the promotion of Ms. Bharti Shah to Chief Executive Officer. She will have the...

21 sep 2018
Pharmaceutical startup Bridge Therapeutics announces the addition of Dr. Bob Raffa as its newest Scientific Advisory Board member. "We are delighted to have Dr. Raffa join our scientific advisory board. His research on pain and addiction medications...

21 sep 2018
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from a Phase 3 clinical study of the investigational product esketamine nasal spray in patients with treatment-resistant depression. Janssen researchers presented these...

21 sep 2018
The "Global Burkitt Lymphoma Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global Burkitt Lymphoma Market to grow at a CAGR of 3.07% during the period 2018-2022. Burkitt lymphoma market 2018-2022,...




News published on 23 february 2018 at 17:30 and distributed by: